<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124877</url>
  </required_header>
  <id_info>
    <org_study_id>A1281197</org_study_id>
    <nct_id>NCT01124877</nct_id>
  </id_info>
  <brief_title>Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</brief_title>
  <official_title>26 Week Open Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of ziprasidone during a
      long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder
      (Manic or Mixed).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in blood pressure and pulse Change from baseline in electrocardiogram (QTc) Change from Baseline in Clinical Global Impression of Severity Scale (CGI-S)</measure>
    <time_frame>weeks 1, 2, 6, 10, 14, 18, 22, and 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Physical exam</measure>
    <time_frame>week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Clinical laboratory tests</measure>
    <time_frame>weeks 2, 6, 18,26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in body weight, height, BMI, BMI z score, and waist circumference</measure>
    <time_frame>weeks 6, 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events -Only number of subjects with adverse events or serious adverse events Columbia Suicide Severity Rating Scale Change from Baseline in Child Depression Rating Scale - Revised (CDRS-R)</measure>
    <time_frame>weeks 1, 2, 6, 10, 14, 18, 22, and 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Young Mania Rating Scale (YMRS)</measure>
    <time_frame>weeks 2, 6, 18, and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Children's Problem Behavior and Aggression Questionnaire (CPBAQ)</measure>
    <time_frame>weeks 2, 6, 18, and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Child Health Questionnaire</measure>
    <time_frame>weeks 6 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in School Placement Questionnaire</measure>
    <time_frame>weeks 6 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CNS Vital Signs Cognitive Test Battery</measure>
    <time_frame>weeks 6 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CNS Vital Signs Cognitive Test Sedation Item</measure>
    <time_frame>weeks 6 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Simpson-Angus Rating Scale (SARS)</measure>
    <time_frame>weeks 1, 2, 6, 10, 14, 18, 22 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Barnes Akathisia Rating Scale (BAS)</measure>
    <time_frame>weeks 1, 2, 6, 10, 14, 18, 22 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>weeks 1, 2, 6, 10, 14, 18, 22 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Childrens Global Assessment Scales</measure>
    <time_frame>weeks 2, 6, 18, and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Tanner Adolescent Pubertal Self-Assessment</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Open</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone oral capsules</intervention_name>
    <description>Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing &lt;45 kg, the doses will range from 20 mg BID to 40 mg BID.</description>
    <arm_group_label>Open</arm_group_label>
    <other_name>Zeldox, Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects must have received study medication in Study A1281196.

          -  In the investigator's opinion, the subject must be likely to continue to benefit from
             antipsychotic therapy and must have been free from any clinically significant safety
             concerns during the preceding double blind study.

        Exclusion Criteria:

          -  Subjects who require treatment with drugs that are known to consistently prolong the
             QT interval.

          -  Subjects who are judged by the investigator as being at imminent risk of suicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281197&amp;StudyName=Safety%20And%20Tolerability%20Of%20Flexible%20Doses%20Of%20Oral%20Ziprasidone%20In%20Children%20And%20Adolescents%20With%20Bipolar%20I%20Disorder%20%28Manic%20Or%20Mixed%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children and Adolescents with Bipolar I Disorder (manic or mixed)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

